Increasingly Efficient Serological Tests Developed with Electrochemiluminescence
|
By LabMedica International staff writers Posted on 17 Jun 2020 |

Image: Schematic representation of the remote electrochemiluminescence (ECL) mechanism (Photo courtesy of University of Bologna).
Diagnostic markers, or biomarkers, are biomolecules (e.g., enzymes, proteins, peptides, and hormones) that can be measured accurately and reproducibly and can precisely predict relevant clinical outcomes or diseases in various populations.
In fact, biomarkers represent a powerful aid in clinical diagnostic and therapeutic monitoring. Therefore, detection, identification, and quantification of such molecules can translate into the development of sophisticated methods and instrumentations for analyzing clinically useful biomarkers.
Medical Chemists at the University of Bologna (Bologna, Italy) and their colleagues discovered an unexpected but highly efficient mechanistic path for electrochemiluminescence (ECL) generation close to the electrode surface (signal enhancement, 128%) using an innovative combination of ECL imaging techniques and electrochemical mapping of radical generation.
The team used through the combination of ECL and microscopy and the use of labeled microbeads, they mapped ECL generation close to the electrode surface (≤1 µm), thus revealing the contribution of an additional pathway to ECL generation, which was unobserved to date. This additional mechanism exhibits a very high efficiency, i.e., 10 times more intense than the signals measured at larger distances (>1 µm).
The scientists identified a family of alternative coreactants/additives, namely branched amines, which may lead to an advantageous overall signal enhancement. In particular, the use of N-dipropyl isobutyl amine (DPIBA) enhances the ECL signal by a maximum of 47% in a commercial immunoassay system for the quantification of several biomarkers, such as thyroid stimulating hormone (TSH), cardiac troponin T, ferritin, and immunoglobulin (Ig)M antibodies against Toxoplasma gondii (Toxo IgM) and hepatitis A (A‐HAV IgM). A series of commercially available Elecsys assays (Roche Diagnostics, Indianapolis, IN) for the detection of those specific biomarkers was used on a Roche cobas e 801 immunoassay analyzer to evaluate the effect of DPIBA on the assay performance.
Alessandra Zanut, PhD, a Physical Chemist and first author of the study, said, “From these results, we managed to identify highly efficient reactants that are able to enhance the sensitivity of this technique way beyond that currently employed for serological tests. With this technique, we obtained an ECL signal enhancement up to 128% compared to current techniques.” The study was published on May 29, 2020 in the journal Nature Communications.
In fact, biomarkers represent a powerful aid in clinical diagnostic and therapeutic monitoring. Therefore, detection, identification, and quantification of such molecules can translate into the development of sophisticated methods and instrumentations for analyzing clinically useful biomarkers.
Medical Chemists at the University of Bologna (Bologna, Italy) and their colleagues discovered an unexpected but highly efficient mechanistic path for electrochemiluminescence (ECL) generation close to the electrode surface (signal enhancement, 128%) using an innovative combination of ECL imaging techniques and electrochemical mapping of radical generation.
The team used through the combination of ECL and microscopy and the use of labeled microbeads, they mapped ECL generation close to the electrode surface (≤1 µm), thus revealing the contribution of an additional pathway to ECL generation, which was unobserved to date. This additional mechanism exhibits a very high efficiency, i.e., 10 times more intense than the signals measured at larger distances (>1 µm).
The scientists identified a family of alternative coreactants/additives, namely branched amines, which may lead to an advantageous overall signal enhancement. In particular, the use of N-dipropyl isobutyl amine (DPIBA) enhances the ECL signal by a maximum of 47% in a commercial immunoassay system for the quantification of several biomarkers, such as thyroid stimulating hormone (TSH), cardiac troponin T, ferritin, and immunoglobulin (Ig)M antibodies against Toxoplasma gondii (Toxo IgM) and hepatitis A (A‐HAV IgM). A series of commercially available Elecsys assays (Roche Diagnostics, Indianapolis, IN) for the detection of those specific biomarkers was used on a Roche cobas e 801 immunoassay analyzer to evaluate the effect of DPIBA on the assay performance.
Alessandra Zanut, PhD, a Physical Chemist and first author of the study, said, “From these results, we managed to identify highly efficient reactants that are able to enhance the sensitivity of this technique way beyond that currently employed for serological tests. With this technique, we obtained an ECL signal enhancement up to 128% compared to current techniques.” The study was published on May 29, 2020 in the journal Nature Communications.
Latest Immunology News
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Cancer-Related Mutations in Immune Cells Linked to Alzheimer’s
Alzheimer’s disease is marked by protein aggregation and inflammatory changes in the brain’s immune system, yet its molecular drivers remain incompletely understood. With aging, human cells accumulate... Read more
Composite Blood Biomarkers Enable Early Detection of Common Cancers
Early diagnosis of colorectal, lung, and ovarian cancers remains challenging, with many patients identified only after tumors have begun to spread. A scalable blood test could expand access to screening,... Read more
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read moreHematology
view channel
Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read moreMicrobiology
view channel
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read more
Label-Free Microscopy Methodd Enables Faster, Quantitative Detection of Malaria
Microscopy of blood smears remains a cornerstone for malaria diagnosis but can be slow, stain-dependent, and operator intensive. With more than 200 million infections and over 600,000 deaths annually,... Read more
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
Pathologists are essential for cancer diagnosis and treatment planning, yet a global workforce shortage is straining services. Nearly 20 million new cases are diagnosed each year, and traditional artificial... Read more
AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
Prostate and breast cancers are among the most commonly diagnosed malignancies worldwide, and heterogeneous disease biology complicates risk stratification and treatment selection. Clinicians increasingly... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more





.jpg)

